Satellos Bioscience Inc. announced on December 17, 2024, and closed on December 20, 2024, a $56,956,500 CAD public offering. The deal included 63,285,000 common shares priced at $0.90 per share and pre-funded warrants at $0.89999 each. Net proceeds after deductions were $52,469,545 CAD, allocated for clinical development of SAT-3247 and corporate purposes.

The offering was conducted on a best-efforts basis, led by Bloom Burton Securities Inc. with Canaccord Genuity Corp., Haywood Securities Inc., and Leede Financial Inc. as co-agents. Legal counsel included Mintz LLP for Satellos and Baker & McKenzie LLP for the agents. Shares were listed on the TSX under "MSCL," while pre-funded warrants were not exchange-listed.